Canada: Weed Wars: Securities Commissions Weigh In On Aurora/CanniMed Hostile Bid

After a joint hearing in mid-December, the Ontario and Saskatchewan securities commissions released identical orders in respect of the unsolicited take-over bid by Aurora Cannabis Inc. for the issued and outstanding common shares of CanniMed Therapeutics Inc. and CanniMed's use of a shareholder rights plan in response to Aurora's unsolicited offer. Although the reasons of the securities commissions have not yet been released, several important implications have emerged from the orders regarding the use of shareholder rights plans as a deal protection measure.


On November 14, 2017, Aurora disclosed that it had submitted an acquisition proposal to the board of directors of CanniMed to acquire CanniMed in consideration for Aurora shares. In its disclosure, Aurora added that it had entered into irrevocable lock-up agreements with shareholders representing 38% of the issued and outstanding CanniMed shares (collectively, the Locked-Up Shareholders). Under the terms of the lock-up agreements, the Locked-Up Shareholders are required to tender their CanniMed shares into Aurora's offer and "vote against other acquisition proposals or actions which might prevent, delay or frustrate Aurora's proposal." Notably, these lock-up agreements do not include termination provisions that would allow the Locked-Up Shareholders to terminate the lock-up agreements in the event that a third party made a superior offer to acquire CanniMed.

Three days later, CanniMed announced that it had entered into an arrangement agreement with Newstrike Resources Ltd. pursuant to which it would acquire all of the issued and outstanding common shares of Newstrike in consideration for CanniMed shares. When Aurora formally launched its unsolicited offer on November 24, 2017, it was made conditional on the non-completion of the Newstrike acquisition.

On November 29, 2017, CanniMed announced that it had adopted a poison pill. The press release stated that the poison pill "prevents Aurora from acquiring any CanniMed shares other than those tendered to its Hostile Bid or from entering into a new lock-up agreement in respect of its Hostile Bid other than those it has already entered into." As to the purpose of the poison pill, the press release indicated that it was to protect CanniMed shareholders from being coerced into tendering to Aurora's bid and to allow for the possibility of another acquisition transaction for CanniMed. Moreover, the press release suggested that the primary purpose of the poison pill was to protect the Newstrike transaction and was "not intended to deter the Hostile Bid or any other bid."

Submissions of the Parties


In its application to the securities commissions, Aurora sought an order to cease-trade the poison pill, which it argued was tactically designed to deter its unsolicited offer and contained certain unusual provisions aimed at restricting CanniMed shareholders from exercising their right to respond to Aurora's offer. In particular, Aurora argued that the terms of the poison pill were inconsistent with National Instrument 62-104 – Take-Over Bids and Issuer Bids (NI 62-104), in several respects. For example, the definition of "Permitted Bid" in the pill did not allow for the reduction of the 105-day minimum deposit period in the event of an "alternative transaction," and the definition required an extension of 10 business days, rather than the statutory 10 calendar days, upon the satisfaction of all bid conditions. In addition, Aurora argued that the pill prevented additional CanniMed shareholders from entering into lock-up agreements with Aurora, whether hard or soft. The definition of beneficial ownership in the poison pill provided that a "Person will be deemed to be the Beneficial Owner of...any securities which are subject to an agreement (including without limitation a Permitted Lock-Up Agreement) to tender or deposit them into any Take-over Bid made by such Person." As a result, Aurora was deemed to own the CanniMed shares held by the Locked-Up Shareholders for purposes of the pill and would be deemed to own any additional shares it might lock up whether by way of hard or soft lock-up.

Aurora also requested relief from the requirement in NI 62-104 that its bid remain open for a minimum of 105 days. In Aurora's view, CanniMed's proposed acquisition of Newstrike "in spirit" constituted an "alternative transaction." Although Aurora acknowledged that the Newstrike transaction did not meet the technical definition of "alternative transaction" in NI 62-104, which would automatically reduce the minimum deposit period for Aurora's offer to 35 days, Aurora made the policy argument that CanniMed did not require the 105-day minimum bid period to consider its bid and seek alternative transactions because it had already proposed the Newstrike acquisition. Aurora also argued that CanniMed shareholders should have the right to make a clear choice between two concurrent transactions. In Aurora's view, the 105-day minimum bid period for its offer would result in the "unequal treatment of offerors" in competing transactions, since CanniMed shareholders were scheduled to vote on the Newstrike acquisition on January 23, 2018, while the minimum bid period for Aurora's bid would expire over six weeks later.


CanniMed sought an order disentitling Aurora from relying on an exemption in NI 62-104 that would allow Aurora to purchase up to 5% of CanniMed's shares in the market. In CanniMed's view, should Aurora be permitted to purchase additional CanniMed shares, it would be in a de facto "blocking position" with respect to any alternative transaction, including the Newstrike acquisition, given the lock-up of 38% of the shares on terms that require holders to vote against any proposal that might frustrate Aurora's bid.

CanniMed Special Committee

The special committee of the CanniMed board sought an order from the securities commissions deeming Aurora and the Locked-Up Shareholders to be "joint actors" for the purpose of Multilateral Instrument 61-101 – Protection of Minority Shareholders in Special Transactions (MI 61-101). Such a determination would require Aurora to comply with the "insider bid" provisions of MI 61-101 and would significantly delay Aurora's offer. In support of its position, the CanniMed special committee argued that it was the Locked-Up Shareholders who approached Aurora to solicit a bid for CanniMed, usurping the function of the board, and that, notably, two directors of the CanniMed board were also directors and/or officers of three Locked-Up Shareholders at the relevant time. According to the CanniMed special committee's submissions, the Locked-Up Shareholders used confidential information obtained from directors of CanniMed to structure Aurora's bid and attempt to frustrate the acquisition of Newstrike. In addition, according to the CanniMed special committee, Newstrike's former financial adviser used confidential information it had obtained while it was engaged by Newstrike before it ceased its engagement in order to advise Aurora with respect to its offer.

The Orders

By orders dated December 22, 2017, the Ontario and Saskatchewan securities commissions cease-traded the poison pill and ordered Aurora to amend its bid circular to disclose any information that was obtained by Aurora from any person who was, at the relevant time, in a "special relationship" with CanniMed for the purpose of insider trading rules, or that was material to Aurora in structuring, or determining the timing of delivering, its proposal or implementing its bid.

However, the securities commissions denied the exemptive relief sought in Aurora's application relating to the characterization of the Newstrike acquisition as an alternative transaction, which would have reduced the 105-day minimum bid period to 35 days and allowed CanniMed shareholders to consider the Newstrike transaction and the unsolicited bid concurrently.

In addition, the securities commissions denied all of the relief sought by CanniMed and the CanniMed special committee, declining to restrict Aurora from purchasing additional shares in the open market or to characterize Aurora and the Locked-Up Shareholders as joint actors.

Implications of the Order

The facts and orders here give rise to numerous interesting and novel issues and will give the commissions the opportunity to provide guidance on a host of topics, from poison pills to deal protections. While we await the written reasons, two takeaways seem clear:

  • When securities regulators adopted amendments to Canada's take-over bid regime in 2016, it was expected that the tactical use of shareholder rights plans to interfere with the normal operation of the take-over bid rules would be met with swift intervention by securities regulators.1 The orders are consistent with this expectation. In a circumstance in which the poison pill was not designed to delay the take-up by Aurora of CanniMed shares tendered into Aurora's offer, but arguably to protect an existing transaction by seeking to limit Aurora's ability to consolidate a blocking position, the securities commissions nonetheless intervened.
  • By denying all the other relief sought by Aurora, CanniMed and the CanniMed special committee, the securities commissions have signalled an intention to strictly adhere to the rules set out in the existing take-over bid regime. Part of the rationale motivating the amendments to the take-over bid regime in 2016 was to introduce greater certainty in the treatment of take-over bids and to reduce the inconsistencies caused by unique poison pill hearings in respect of unsolicited take-over bids. The orders indicate that the securities commissions are keen to preserve the uniform and predictable treatment of take-over bids, and that they will be reluctant to vary the rules in the heat of battle.

What to Watch For

We will provide additional commentary when the written reasons are released. When they are, we will be keeping an eye out for the following:

  • There is limited case law (from both the courts and securities regulators) assessing the appropriateness of deal protections generally. Delaware courts have historically been suspicious of excessively strong deal protections, especially when they operate to make a transaction a fait accompli prior to a shareholder vote. We will be interested to see whether the securities commissions take this opportunity to comment on deal protections negotiated in transaction documents and the use of hard lock-up agreements.
  • We will also be interested to see whether the securities commissions comment on the ability of a target company to pursue an acquisition transaction in the context of defending against an unsolicited take-over bid. This form of take-over defence is unusual in Canada, and it is an open question whether securities regulators will apply to an acquisition transaction in a hostile bid context an analysis similar to that applicable to private placements as a defensive tactic.2
  • We expect the decision will focus on the potential disclosure of confidential information by insiders and advisers, including the directors on the CanniMed board who represented three Locked-Up Shareholders, and by the former financial advisers to Newstrike. The securities commissions were clearly troubled by the possibility that persons in a special relationship with CanniMed may have shared information with Aurora. Although they were not prepared to go so far as to deem Aurora and the Locked-Up Shareholders to be joint actors, they cleverly laid the problem at the bidder's feet, leaving Aurora to sort out the sources of its information and to disclose it in a document to which director and officer liability attaches.
  • We expect the commissions' reasons for not deeming the bidder and Locked-Up Shareholders to be joint actors will provide helpful illumination of this often grey and hazy concept.


1 See the Davies bulletin dated February 25, 2016, titled Take-over Bid Code Reset: 50-10-105.

2 See the Davies bulletin dated January 12, 2017, titled If Pills Are Out, Are Private Placements In?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions